title: Comparison of two oral antibiotics, roxithromycin and amoxicillin plus clavulanic acid, in lower respiratory tract infections.
abstract: In a randomized, multicenter, open-label study, 490 ambulatory adult patients with lower respiratory tract infection (LRTI) were randomized to roxithromycin (ROX) 150 mg b.i.d. orally (n = 244) or amoxicillin plus clavulanic acid (AMX + CA) as 500 mg AMX + 125 mg CA t.i.d orally (n = 24). Clinical results were analyzed in 477 patients with acute bronchitis (79%), chronic bronchitis (CB) (14%), and pneumonia (7%). There were significantly more patients with underlying disease (cardiovascular diseases, p = 0.045; and alcoholism, (p less than 0.001), and more patients over the age of 65 years (p = 0.045) in the ROX group. Overall clinical efficacy was similar in both groups: 88% (206:235) in the ROX group and 85% (205:242) in the AMX + CA group. Side effects were reported in 67 cases (28%) in the AMX + CA group and in 21 cases (9%) in the ROX group (p less than 0.0001), causing withdrawal in 21 and three cases, respectively (p less than 0.001). Thus, despite being administered to a significantly older and more ill group of patients with LRTI, roxithromycin was as effective as amoxicillin plus clavulanic acid and better tolerated.
authors.affiliation: Thoracic Department Pitié Salpêtrière Hospital, Paris, France.
authors.forename: B
authors.initials: B
authors.lastname: Dautzenberg
authors.forename: A
authors.initials: A
authors.lastname: Scheimberg
authors.forename: C
authors.initials: C
authors.lastname: Brambilla
authors.forename: P
authors.initials: P
authors.lastname: Camus
authors.forename: P
authors.initials: P
authors.lastname: Godard
authors.forename: J C
authors.initials: JC
authors.lastname: Guerin
authors.forename: E
authors.initials: E
authors.lastname: Lemarie
authors.forename: Y
authors.initials: Y
authors.lastname: Rezvani
authors.forename: M
authors.initials: M
authors.lastname: Rosembaum
authors.forename: E
authors.initials: E
authors.lastname: Tuchais
mesh_terms: D000208:Acute Disease; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000658:Amoxicillin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019980:Amoxicillin-Potassium Clavulanate Combination; D001991:Bronchitis / Q000188:drug therapy*; D002908:Chronic Disease; D002969:Clavulanic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004361:Drug Tolerance; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000188:drug therapy*; D015575:Roxithromycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D002969:Clavulanic Acids; D015575:Roxithromycin; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin